GrippeAllemagneV4, Main, Exploration, bibRecord, 000139

Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: a test-negative case-control study.

Identifieur interne : 000139 ( Main/Exploration ); précédent : 000138; suivant : 000140

Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: a test-negative case-control study.

Auteurs : Carina Helmeke [Allemagne] ; Lutz Gr Fe [Allemagne] ; Hanns-Martin Irmscher [Allemagne] ; Constanze Gottschalk [Allemagne] ; Ioannis Karagiannis [Suède] ; Hanna Oppermann [Allemagne]

Source :

PloS one [ 1932-6203 ] ; 2015.

RBID : pubmed:25885063

Descripteurs français

KwdFr :
- ARN viral (analyse), Adolescent (MeSH), Allemagne (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Femelle (MeSH), Grippe humaine (prévention et contrôle), Humains (MeSH), Modèles logistiques (MeSH), Mâle (MeSH), Odds ratio (MeSH), Résultat thérapeutique (MeSH), Sous-type H1N1 du virus de la grippe A (génétique), Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H3N2 du virus de la grippe A (génétique), Sous-type H3N2 du virus de la grippe A (immunologie), Vaccins antigrippaux (immunologie), Vaccins antigrippaux (normes), Vaccins atténués (immunologie), Vaccins atténués (normes), Vaccins inactivés (immunologie), Vaccins inactivés (normes), Virus influenza B (génétique), Virus influenza B (immunologie), Études cas-témoins (MeSH).
MESH :
- analyse : ARN viral.
- génétique : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Virus influenza B.
- immunologie : Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Vaccins antigrippaux, Vaccins atténués, Vaccins inactivés, Virus influenza B.
- normes : Vaccins antigrippaux, Vaccins atténués, Vaccins inactivés.
- prévention et contrôle : Grippe humaine.
- Adolescent, Allemagne, Enfant, Enfant d'âge préscolaire, Femelle, Humains, Modèles logistiques, Mâle, Odds ratio, Résultat thérapeutique, Études cas-témoins.
Wicri :
- geographic : Allemagne.

English descriptors

KwdEn :
- Adolescent (MeSH), Case-Control Studies (MeSH), Child (MeSH), Child, Preschool (MeSH), Female (MeSH), Germany (MeSH), Humans (MeSH), Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H3N2 Subtype (genetics), Influenza A Virus, H3N2 Subtype (immunology), Influenza B virus (genetics), Influenza B virus (immunology), Influenza Vaccines (immunology), Influenza Vaccines (standards), Influenza, Human (prevention & control), Logistic Models (MeSH), Male (MeSH), Odds Ratio (MeSH), RNA, Viral (analysis), Treatment Outcome (MeSH), Vaccines, Attenuated (immunology), Vaccines, Attenuated (standards), Vaccines, Inactivated (immunology), Vaccines, Inactivated (standards).
MESH :
- chemical , analysis : RNA, Viral.
- chemical , immunology : Influenza Vaccines, Vaccines, Attenuated, Vaccines, Inactivated.
- chemical , standards : Influenza Vaccines, Vaccines, Attenuated, Vaccines, Inactivated.
- geographic : Germany.
- genetics : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus.
- immunology : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza B virus.
- prevention & control : Influenza, Human.
- Adolescent, Case-Control Studies, Child, Child, Preschool, Female, Humans, Logistic Models, Male, Odds Ratio, Treatment Outcome.

Abstract

A live attenuated influenza vaccine has been available in Germany since the influenza season 2012/13, which is approved for children aged 2-17 years. Using data from our laboratory-based surveillance system, we described the circulation of influenza and non-influenza respiratory viruses during the influenza season 2012/13 in Saxony-Anhalt. We estimated the effectiveness of live and inactivated trivalent influenza vaccines in preventing laboratory-confirmed cases among children and adolescents. From week 40/2012 to 19/2013, sentinel paediatricians systematically swabbed acute respiratory illness patients for testing of influenza and 5 non-influenza viruses by PCR. We compared influenza cases and influenza-negative controls. Among children aged 2-17 years, we calculated overall and vaccine type-specific effectiveness against laboratory-confirmed influenza, stratified by age group (2-6; 7-17 years). We used multivariable logistic regression to adjust estimates for age group, sex and month of illness. Out of 1,307 specimens, 647 (35%) were positive for influenza viruses and 189 (15%) for at least one of the tested non-influenza viruses. For vaccine effectiveness estimation, we included 834 patients (mean age 7.3 years, 53% males) in our analysis. Of 347 (42%) influenza-positive specimens, 61 (18%) were positive for A(H1N1)pdm09, 112 (32%) for A(H3N2) and 174 (50%) for influenza B virus. The adjusted overall vaccine effectiveness including both age groups was 38% (95% CI: 0.8-61%). The adjusted effectiveness for inactivated vaccines was 37% (95% CI: -35-70%) and for live vaccines 84% (95% CI: 45-95%). Effectiveness for the live vaccine was higher in 2-6 year-old children (90%, 95% CI: 20-99%) than in children aged 7-17 years (74%, 95% CI: -32-95%). Our study of the strong influenza season in 2012/13 suggests a high preventive effect of live attenuated influenza vaccine especially among young children, which could not be reached by inactivated vaccines. We recommend the use of live attenuated influenza vaccines in children unless there are contraindications.

DOI: 10.1371/journal.pone.0122910
PubMed: 25885063
PubMed Central: PMC4401761

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000140
to stream Main, to step Curation: 000140

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: a test-negative case-control study.</title>
<author><name sortKey="Helmeke, Carina" sort="Helmeke, Carina" uniqKey="Helmeke C" first="Carina" last="Helmeke">Carina Helmeke</name>
<affiliation wicri:level="3"><nlm:affiliation>European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden; State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden; State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg</wicri:regionArea>
<placeName><region type="land" nuts="2">Saxe-Anhalt</region>
<settlement type="city">Magdebourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gr Fe, Lutz" sort="Gr Fe, Lutz" uniqKey="Gr Fe L" first="Lutz" last="Gr Fe">Lutz Gr Fe</name>
<affiliation wicri:level="3"><nlm:affiliation>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg</wicri:regionArea>
<placeName><region type="land" nuts="2">Saxe-Anhalt</region>
<settlement type="city">Magdebourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Irmscher, Hanns Martin" sort="Irmscher, Hanns Martin" uniqKey="Irmscher H" first="Hanns-Martin" last="Irmscher">Hanns-Martin Irmscher</name>
<affiliation wicri:level="3"><nlm:affiliation>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg</wicri:regionArea>
<placeName><region type="land" nuts="2">Saxe-Anhalt</region>
<settlement type="city">Magdebourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gottschalk, Constanze" sort="Gottschalk, Constanze" uniqKey="Gottschalk C" first="Constanze" last="Gottschalk">Constanze Gottschalk</name>
<affiliation wicri:level="3"><nlm:affiliation>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg</wicri:regionArea>
<placeName><region type="land" nuts="2">Saxe-Anhalt</region>
<settlement type="city">Magdebourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Karagiannis, Ioannis" sort="Karagiannis, Ioannis" uniqKey="Karagiannis I" first="Ioannis" last="Karagiannis">Ioannis Karagiannis</name>
<affiliation wicri:level="3"><nlm:affiliation>European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oppermann, Hanna" sort="Oppermann, Hanna" uniqKey="Oppermann H" first="Hanna" last="Oppermann">Hanna Oppermann</name>
<affiliation wicri:level="3"><nlm:affiliation>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg</wicri:regionArea>
<placeName><region type="land" nuts="2">Saxe-Anhalt</region>
<settlement type="city">Magdebourg</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25885063</idno>
<idno type="pmid">25885063</idno>
<idno type="doi">10.1371/journal.pone.0122910</idno>
<idno type="pmc">PMC4401761</idno>
<idno type="wicri:Area/Main/Corpus">000140</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000140</idno>
<idno type="wicri:Area/Main/Curation">000140</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000140</idno>
<idno type="wicri:Area/Main/Exploration">000140</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: a test-negative case-control study.</title>
<author><name sortKey="Helmeke, Carina" sort="Helmeke, Carina" uniqKey="Helmeke C" first="Carina" last="Helmeke">Carina Helmeke</name>
<affiliation wicri:level="3"><nlm:affiliation>European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden; State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden; State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg</wicri:regionArea>
<placeName><region type="land" nuts="2">Saxe-Anhalt</region>
<settlement type="city">Magdebourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gr Fe, Lutz" sort="Gr Fe, Lutz" uniqKey="Gr Fe L" first="Lutz" last="Gr Fe">Lutz Gr Fe</name>
<affiliation wicri:level="3"><nlm:affiliation>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg</wicri:regionArea>
<placeName><region type="land" nuts="2">Saxe-Anhalt</region>
<settlement type="city">Magdebourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Irmscher, Hanns Martin" sort="Irmscher, Hanns Martin" uniqKey="Irmscher H" first="Hanns-Martin" last="Irmscher">Hanns-Martin Irmscher</name>
<affiliation wicri:level="3"><nlm:affiliation>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg</wicri:regionArea>
<placeName><region type="land" nuts="2">Saxe-Anhalt</region>
<settlement type="city">Magdebourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Gottschalk, Constanze" sort="Gottschalk, Constanze" uniqKey="Gottschalk C" first="Constanze" last="Gottschalk">Constanze Gottschalk</name>
<affiliation wicri:level="3"><nlm:affiliation>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg</wicri:regionArea>
<placeName><region type="land" nuts="2">Saxe-Anhalt</region>
<settlement type="city">Magdebourg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Karagiannis, Ioannis" sort="Karagiannis, Ioannis" uniqKey="Karagiannis I" first="Ioannis" last="Karagiannis">Ioannis Karagiannis</name>
<affiliation wicri:level="3"><nlm:affiliation>European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Oppermann, Hanna" sort="Oppermann, Hanna" uniqKey="Oppermann H" first="Hanna" last="Oppermann">Hanna Oppermann</name>
<affiliation wicri:level="3"><nlm:affiliation>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg</wicri:regionArea>
<placeName><region type="land" nuts="2">Saxe-Anhalt</region>
<settlement type="city">Magdebourg</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">PloS one</title>
<idno type="eISSN">1932-6203</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term>
<term>Case-Control Studies (MeSH)</term>
<term>Child (MeSH)</term>
<term>Child, Preschool (MeSH)</term>
<term>Female (MeSH)</term>
<term>Germany (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Influenza A Virus, H1N1 Subtype (genetics)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza A Virus, H3N2 Subtype (genetics)</term>
<term>Influenza A Virus, H3N2 Subtype (immunology)</term>
<term>Influenza B virus (genetics)</term>
<term>Influenza B virus (immunology)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Influenza Vaccines (standards)</term>
<term>Influenza, Human (prevention & control)</term>
<term>Logistic Models (MeSH)</term>
<term>Male (MeSH)</term>
<term>Odds Ratio (MeSH)</term>
<term>RNA, Viral (analysis)</term>
<term>Treatment Outcome (MeSH)</term>
<term>Vaccines, Attenuated (immunology)</term>
<term>Vaccines, Attenuated (standards)</term>
<term>Vaccines, Inactivated (immunology)</term>
<term>Vaccines, Inactivated (standards)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>ARN viral (analyse)</term>
<term>Adolescent (MeSH)</term>
<term>Allemagne (MeSH)</term>
<term>Enfant (MeSH)</term>
<term>Enfant d'âge préscolaire (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Grippe humaine (prévention et contrôle)</term>
<term>Humains (MeSH)</term>
<term>Modèles logistiques (MeSH)</term>
<term>Mâle (MeSH)</term>
<term>Odds ratio (MeSH)</term>
<term>Résultat thérapeutique (MeSH)</term>
<term>Sous-type H1N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H3N2 du virus de la grippe A (génétique)</term>
<term>Sous-type H3N2 du virus de la grippe A (immunologie)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins antigrippaux (normes)</term>
<term>Vaccins atténués (immunologie)</term>
<term>Vaccins atténués (normes)</term>
<term>Vaccins inactivés (immunologie)</term>
<term>Vaccins inactivés (normes)</term>
<term>Virus influenza B (génétique)</term>
<term>Virus influenza B (immunologie)</term>
<term>Études cas-témoins (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>RNA, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="standards" xml:lang="en"><term>Influenza Vaccines</term>
<term>Vaccines, Attenuated</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" type="geographic" xml:lang="en"><term>Germany</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>ARN viral</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
<term>Vaccins inactivés</term>
<term>Virus influenza B</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza B virus</term>
</keywords>
<keywords scheme="MESH" qualifier="normes" xml:lang="fr"><term>Vaccins antigrippaux</term>
<term>Vaccins atténués</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Case-Control Studies</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Female</term>
<term>Humans</term>
<term>Logistic Models</term>
<term>Male</term>
<term>Odds Ratio</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Allemagne</term>
<term>Enfant</term>
<term>Enfant d'âge préscolaire</term>
<term>Femelle</term>
<term>Humains</term>
<term>Modèles logistiques</term>
<term>Mâle</term>
<term>Odds ratio</term>
<term>Résultat thérapeutique</term>
<term>Études cas-témoins</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Allemagne</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A live attenuated influenza vaccine has been available in Germany since the influenza season 2012/13, which is approved for children aged 2-17 years. Using data from our laboratory-based surveillance system, we described the circulation of influenza and non-influenza respiratory viruses during the influenza season 2012/13 in Saxony-Anhalt. We estimated the effectiveness of live and inactivated trivalent influenza vaccines in preventing laboratory-confirmed cases among children and adolescents. From week 40/2012 to 19/2013, sentinel paediatricians systematically swabbed acute respiratory illness patients for testing of influenza and 5 non-influenza viruses by PCR. We compared influenza cases and influenza-negative controls. Among children aged 2-17 years, we calculated overall and vaccine type-specific effectiveness against laboratory-confirmed influenza, stratified by age group (2-6; 7-17 years). We used multivariable logistic regression to adjust estimates for age group, sex and month of illness. Out of 1,307 specimens, 647 (35%) were positive for influenza viruses and 189 (15%) for at least one of the tested non-influenza viruses. For vaccine effectiveness estimation, we included 834 patients (mean age 7.3 years, 53% males) in our analysis. Of 347 (42%) influenza-positive specimens, 61 (18%) were positive for A(H1N1)pdm09, 112 (32%) for A(H3N2) and 174 (50%) for influenza B virus. The adjusted overall vaccine effectiveness including both age groups was 38% (95% CI: 0.8-61%). The adjusted effectiveness for inactivated vaccines was 37% (95% CI: -35-70%) and for live vaccines 84% (95% CI: 45-95%). Effectiveness for the live vaccine was higher in 2-6 year-old children (90%, 95% CI: 20-99%) than in children aged 7-17 years (74%, 95% CI: -32-95%). Our study of the strong influenza season in 2012/13 suggests a high preventive effect of live attenuated influenza vaccine especially among young children, which could not be reached by inactivated vaccines. We recommend the use of live attenuated influenza vaccines in children unless there are contraindications. </div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25885063</PMID>
<DateCompleted><Year>2016</Year>
<Month>01</Month>
<Day>14</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>10</Volume>
<Issue>4</Issue>
<PubDate><Year>2015</Year>
</PubDate>
</JournalIssue>
<Title>PloS one</Title>
<ISOAbbreviation>PLoS ONE</ISOAbbreviation>
</Journal>
<ArticleTitle>Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: a test-negative case-control study.</ArticleTitle>
<Pagination><MedlinePgn>e0122910</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0122910</ELocationID>
<Abstract><AbstractText>A live attenuated influenza vaccine has been available in Germany since the influenza season 2012/13, which is approved for children aged 2-17 years. Using data from our laboratory-based surveillance system, we described the circulation of influenza and non-influenza respiratory viruses during the influenza season 2012/13 in Saxony-Anhalt. We estimated the effectiveness of live and inactivated trivalent influenza vaccines in preventing laboratory-confirmed cases among children and adolescents. From week 40/2012 to 19/2013, sentinel paediatricians systematically swabbed acute respiratory illness patients for testing of influenza and 5 non-influenza viruses by PCR. We compared influenza cases and influenza-negative controls. Among children aged 2-17 years, we calculated overall and vaccine type-specific effectiveness against laboratory-confirmed influenza, stratified by age group (2-6; 7-17 years). We used multivariable logistic regression to adjust estimates for age group, sex and month of illness. Out of 1,307 specimens, 647 (35%) were positive for influenza viruses and 189 (15%) for at least one of the tested non-influenza viruses. For vaccine effectiveness estimation, we included 834 patients (mean age 7.3 years, 53% males) in our analysis. Of 347 (42%) influenza-positive specimens, 61 (18%) were positive for A(H1N1)pdm09, 112 (32%) for A(H3N2) and 174 (50%) for influenza B virus. The adjusted overall vaccine effectiveness including both age groups was 38% (95% CI: 0.8-61%). The adjusted effectiveness for inactivated vaccines was 37% (95% CI: -35-70%) and for live vaccines 84% (95% CI: 45-95%). Effectiveness for the live vaccine was higher in 2-6 year-old children (90%, 95% CI: 20-99%) than in children aged 7-17 years (74%, 95% CI: -32-95%). Our study of the strong influenza season in 2012/13 suggests a high preventive effect of live attenuated influenza vaccine especially among young children, which could not be reached by inactivated vaccines. We recommend the use of live attenuated influenza vaccines in children unless there are contraindications. </AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Helmeke</LastName>
<ForeName>Carina</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden; State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gräfe</LastName>
<ForeName>Lutz</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Irmscher</LastName>
<ForeName>Hanns-Martin</ForeName>
<Initials>HM</Initials>
<AffiliationInfo><Affiliation>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gottschalk</LastName>
<ForeName>Constanze</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Karagiannis</LastName>
<ForeName>Ioannis</ForeName>
<Initials>I</Initials>
<AffiliationInfo><Affiliation>European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Oppermann</LastName>
<ForeName>Hanna</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>State Agency for Consumer Protection Saxony-Anhalt, Department of Hygiene, Magdeburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>04</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>PLoS One</MedlineTA>
<NlmUniqueID>101285081</NlmUniqueID>
<ISSNLinking>1932-6203</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014613" MajorTopicYN="N">Vaccines, Attenuated</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>10</Month>
<Day>07</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>02</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>4</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>4</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>1</Month>
<Day>15</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25885063</ArticleId>
<ArticleId IdType="doi">10.1371/journal.pone.0122910</ArticleId>
<ArticleId IdType="pii">PONE-D-14-37554</ArticleId>
<ArticleId IdType="pmc">PMC4401761</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Pediatr Infect Dis J. 2006 Oct;25(10):870-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17006279</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2006 Oct;25(10):860-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17006278</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2007 Feb 15;356(7):685-96</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17301299</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Infect. 2007 Jul;13(7):665-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17441977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2008 Nov;122(5):911-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18977968</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2012 Jan;12(1):36-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22032844</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2012 Jan 20;30(5):886-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22155144</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2549-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22410646</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biotechniques. 2000 Jul;29(1):88-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10907082</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2002 Dec;40(12):4418-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12454129</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2003 Jun;70(2):228-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12696109</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2013 Jan;56(1):11-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23183869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Public Health. 2012;12:938</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23113995</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2014;14:40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24450996</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2014;19(6). pii: 20701</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24556348</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Infect. 2014 Sep;142(9):1809-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24814635</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2010;5(4):e9966</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20376359</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2010 May 1;4(3):141-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20409210</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2010 Oct 28;28(46):7381-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20851086</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatr Infect Dis J. 2011 Mar;30(3):203-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20935591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2011;6(7):e19932</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21789163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs. 2011 Aug 20;71(12):1591-622</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21861544</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2004 Jan 29;350(5):443-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14749452</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2004 Mar;42(3):981-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15004041</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Virol. 2004 Jun;30(2):150-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15125871</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2004 Jul;42(7):3212-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15243084</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 1998 May 14;338(20):1405-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9580647</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pediatrics. 2005 Jul;116(1):153-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15995046</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Chem. 2005 Aug;51(8):1508-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16040843</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2006 Oct 15;194(8):1032-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16991077</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pediatr. 2006 Dec;149(6):755-762</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17137887</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Suède</li>
</country>
<region><li>Saxe-Anhalt</li>
<li>Svealand</li>
</region>
<settlement><li>Magdebourg</li>
<li>Stockholm</li>
</settlement>
</list>
<tree><country name="Allemagne"><region name="Saxe-Anhalt"><name sortKey="Helmeke, Carina" sort="Helmeke, Carina" uniqKey="Helmeke C" first="Carina" last="Helmeke">Carina Helmeke</name>
</region>
<name sortKey="Gottschalk, Constanze" sort="Gottschalk, Constanze" uniqKey="Gottschalk C" first="Constanze" last="Gottschalk">Constanze Gottschalk</name>
<name sortKey="Gr Fe, Lutz" sort="Gr Fe, Lutz" uniqKey="Gr Fe L" first="Lutz" last="Gr Fe">Lutz Gr Fe</name>
<name sortKey="Irmscher, Hanns Martin" sort="Irmscher, Hanns Martin" uniqKey="Irmscher H" first="Hanns-Martin" last="Irmscher">Hanns-Martin Irmscher</name>
<name sortKey="Oppermann, Hanna" sort="Oppermann, Hanna" uniqKey="Oppermann H" first="Hanna" last="Oppermann">Hanna Oppermann</name>
</country>
<country name="Suède"><region name="Svealand"><name sortKey="Karagiannis, Ioannis" sort="Karagiannis, Ioannis" uniqKey="Karagiannis I" first="Ioannis" last="Karagiannis">Ioannis Karagiannis</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000139 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000139 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    GrippeAllemagneV4
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:25885063
   |texte=   Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: a test-negative case-control study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:25885063" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeAllemagneV4

This area was generated with Dilib version V0.6.35.
Data generation: Mon Aug 10 17:53:30 2020. Site generation: Sat Mar 27 17:40:37 2021

	Serveur d'exploration sur la grippe en Allemagne
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la grippe en Allemagne

Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: a test-negative case-control study.

Effectiveness of the 2012/13 trivalent live and inactivated influenza vaccines in children and adolescents in Saxony-Anhalt, Germany: a test-negative case-control study.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki